comparemela.com

Page 7 - Neuropace Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

NeuroPace Inc Chief Medical Officer Martha Morrell Sells 17,589 Shares

On February 5, 2024, Chief Medical Officer Martha Morrell sold 17,589 shares of NeuroPace Inc (NASDAQ:NPCE) according to a recent SEC filing.

Neuropace incMartha morrellChief medical officer

NeuroPace Inc Chief Medical Officer Martha Morrell Sells 13,848 Shares

NeuroPace Inc (NASDAQ:NPCE), a company specializing in the development and commercialization of implantable devices designed to treat neurological disorders through responsive neurostimulation, has reported an insider sell transaction.

Neuropace incChief medical officerNeurological disordersMartha morrell

Leerink Partnrs Reiterates Outperform Rating for NeuroPace (NASDAQ:NPCE)

Leerink Partnrs Reiterates Outperform Rating for NeuroPace (NASDAQ:NPCE)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United statesMartha morrellLeerink partnrsSecurities exchange commissionGeode capital managementMorgan stanleyJpmorgan chase coWells fargo companyCitadel advisorsBlackrock incKent lake capitalNeuropace incGet free reportStreet capitalWells fargoExchange commission

NeuroPace s (NPCE) Outperform Rating Reiterated at Leerink Partnrs

NeuroPace s (NPCE) Outperform Rating Reiterated at Leerink Partnrs
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United statesMartha morrellLeerink partnrsRenaissance technologiesCitigroup incJpmorgan chase coGeode capital managementCantor fitzgeraldMorgan stanleyBlackrock incNeuropace incGet free reportStreet capitalStreet corpCapital managementNeuropace daily

SVB Leerink Initiates Coverage on NeuroPace (NASDAQ:NPCE)

Investment analysts at SVB Leerink began coverage on shares of NeuroPace (NASDAQ:NPCE – Get Free Report) in a research note issued to investors on Tuesday, Briefing.com reports. The firm set an “outperform” rating and a $22.00 price target on the stock. SVB Leerink’s price target indicates a potential upside of 49.15% from the company’s previous […]

United statesMartha morrellCitigroup incCantor fitzgeraldKent lake capitalMorgan stanleyWells fargo companyNeuropace company profileVanguard group incJpmorgan chase coNeuropace incGet free reportStreet capitalWells fargoLake capitalNeuropace daily

vimarsana © 2020. All Rights Reserved.